Sotatercept denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for sotatercept are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Requires Step Therapy for Sotatercept

Step therapy — sometimes called "fail-first" — requires that a patient try one or more less-expensive drugs before the insurer will cover the requested medication. For sotatercept, UHC's step therapy protocol typically requires documented use of other PAH-approved therapies before approving coverage. This policy is legal and common, but it is not absolute: step therapy requirements can be overridden when the clinical record shows that required steps are contraindicated, have already been tried and failed, or would cause medically unacceptable delay for a patient with serious disease.

Many states also have enacted step-therapy override laws requiring insurers to grant exceptions when clinical criteria are met — check whether your plan is subject to your state's insurance laws (fully-insured plans) or is governed by ERISA (most employer-sponsored plans).

## Your Appeal Rights

• Step-therapy exception request: Most plans, including UHC, must offer a step-therapy exception process. The prescribing physician submits a request with documentation showing that required step drugs are inappropriate, already failed, or that sotatercept is specifically required.
• Internal appeal (ERISA §503 / ACA §2719): If the exception is denied, file a formal written internal appeal. Submit the complete prior treatment record and specialist letter.
• External review: After internal appeal, request independent external review by an IRO. External reviewers apply clinical standards and are not bound by the plan's step-therapy protocol. File within the deadline on your Explanation of Benefits — typically approximately four months.
• Expedited review: PAH can deteriorate rapidly. If delay poses a serious health risk, request expedited internal and external review simultaneously.
• State step-therapy override laws: If your plan is fully insured (not ERISA), your state may require the insurer to grant an exception when the prescriber certifies specific clinical criteria. Ask your state insurance department or a patient advocate.

## Documentation to Gather

1. Prior therapy record: Dated records for each PAH therapy UHC requires as a prior step — start date, end date, dose titration history, reason discontinued or deemed inadequate. 2. Clinical response documentation: Objective measures (functional assessments, imaging, hemodynamic data if available) showing the outcome of each prior therapy. 3. Contraindication or intolerance documentation: If any required step drug is contraindicated or not tolerated, chart documentation and the prescriber's assessment. 4. Current clinical severity: Most recent functional assessment, specialist notes on disease progression, and risk stratification. 5. Specialist medical-necessity letter: A letter from the PAH specialist addressing each required step by name and explaining why sotatercept is now the appropriate therapy.

## Criteria-Mapping Structure

Obtain UHC's published step-therapy criteria for sotatercept. List each required prior step. For each, document in the chart record: (a) whether it was tried — with dates; (b) the outcome; or (c) why it was not appropriate. This structured mapping is the clearest way to demonstrate that the step-therapy requirement has been satisfied or that a clinical override is warranted.